Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$32.96 USD
+0.09 (0.27%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $32.94 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Kymera Therapeutics, Inc. [KYMR]
Reports for Purchase
Showing records 21 - 34 ( 34 total )
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-474''s Proof of Biology Data in 2H22 Is All About Safety and Cytokine Suppression
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-474 Data Places Kymera as a TPD Leader in the Inflammatory Disease Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAT3 Degradation in Combination with anti-PD1 Therapy is a Promising Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-474 Shows Robust Degradation of IRAK4 and Decreases Inflammatory Cytokine Production
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Impact of the Interim Data of KT-474 on Kymera''s Pipeline and the Landscape - Our Insights
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kymera on Pace to Advance Multiple Programs to Clinical Trials in 2021; Reit Buy and $85 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KT-413 Dual-Protein Degrader Had Improved Synergistic Effect Over Single Agent Inhibitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expecting Multiple Advancements Into Clinical Stage Programs for Kymera in 2021; Reit Buy and $85 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Kymera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data for IRAKIMiD and STAT3 Degraders Presented at ASH Support Clinical Development in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A